Until recently, most laboratories used radioimmunoassay (RIA) methods for the measurement of serum luteinizing hormone (LH) concentration. A recognized problem of these methods has been non-specific interference particularly at low concentrations of LH.' Immunometric assays (IMA) for LH are now readily available. These assays are generally two-site 'sandwich' type assays utilizing monoclonal antibodies as the labelled antibody and a monoclonal or polyclonal antibody as the solid phased antibody. It has been reported that non-specific interference in IMA is less than that found in RIA, at least when 'zero analyte', e.g. serum from hypopituitary patients, irnmunoaffinity stripped, or horse serum is measured.* A number of studies have recently been reported where the ratio of bioactive to immunoreative (B:I) LH has been used as an index of the overall biopotency of LH in a variety of physiological and clinical conditions. A recent paper has suggested that over-estimation of LH concentrations by RIA (compared to IMA measurements) may result in misleading B:I ratios particularly at low LH concentration^.^ This study, however, assumed that IMA gave an accurate result for LH which may not be the case.
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We have developed a two-site immunoradiometric assay (IRMA) for LH using commercially available reagents and compared it to the RIA then in routine use in the department using patient samples.
The data was analysed by Deming's method4 and by the use of a difference plot as described by Bland and Altman (1986).5 In this analysis the difference between the results, expressed as a percentage of the mean of the two estimations for an individual sample, is plotted against the
mean. This should give clearer information about the agreement between the two methods than regression analysis.
METHODS

Anti-LH monoclonal antibody was purchased
from Biogenesis Ltd (Bournemouth, UK) and was labelled by the Chloramine T method to a specific activity of 0.74 MBq/pg protein. The solid phased antibody was a sheep anti-LH polyclonal obtained from SAPU (Carluke, UK) coupled to Dynospheres (Dyno Industrier, Norway) in this laboratory. LH standards (IRP 68/40, NIBSC, London, UK) in the range 0.61-92 IU/L were prepared in pig serum (Serotec, Oxford, UK). Within assay coefficient of variation (CV) was < 10% across the range of the assay. Between assay CV was < 10% in the range 2.5-9-0 IU/L.
The assay detection limit calculated by the method of Fraser and Wilde (1986)6 was 0.5 IU/L.
The RIA was an 'in house' method. The antibody was from Professor W R Butt (Birmingham, UK). The IZ5I-LH was from Chelsea Hospital (London, UK). LH standards (IRP 68/40) in the range 1 -2-47 IU/L were prepared in assay diluent (0.05 M phosphate buffer pH 7-4+0.5% bovine serum albumin). The separation of free and bound radioactivity was by Sac-cell (IDS, UK). Withinassay CV was < 15% in the range 2-7->47 IU/L and between-batch CV was 11 -15% in the range 4.5-22 IU/L. The detection limit calculated as above was 1.4 IU/L. Serum LH concentration was measured by both methods in 84 specimens received routinely in the laboratory for measurement of gonadotrophins.
RESULTS AND DISCUSSION
Figure l(a) shows the relationship between LH results obtained in the RIA and the IRMA. The regression line was y=0.97x-2.08. The difference plot is shown in Fig. l(b) . In this plot a percentage difference of 110% means that the Mean value l x + y ) / 2
FIGURE 1 . (a) Relationship between luteinizing hormone [IU/L] measured in RIA and IRMA. A =line of equivalence. (b) Dgference plot for luteinizing hormone data where x is the RIA result and y i s the IRMA result. %difference= [x-y/O.S(x+y)] x 100.
RIA result was 3 . 5 x the IRMA; similarly a percentage difference of -30% means that the RIA result was approximately 0-7 x the IRMA. In Fig.   l(a) all the data points are clustered near to the line and might suggest good between method agreement. The correlation coefficient as 0 -97 but this merely confirms that the results are linearly related. The difference plot ( Fig. l(b) ) shows clearly that there are larger differences between the IRMA and the RIA than can be seen in Fig. l(a) . In particular the difference plot shows that although agreement is good at higher concentrations of LH, the RIA is positively biased with respect to the IRMA at low doses of LH (results below the detection limit of either assay were excluded). Although the differences in results might be due to the presence of cross-reacting substances, it is now thought more likely to be due to matrix effects.' This study has demonstrated the limitations of regression analysis in determining the agreement between two immunoassay methods for LH. The difference plot allows a much clearer interpretation of the data and the identification of dose-related bias. We are currently examining the wider value of the difference plot in method comparisons.
The importance of quantifying dose-related bias in immunoassay has been highlighted by Jaakkola et al. (1990)4 who studied B : I ratios for LH in a number of clinical conditions using both RIA and IRMA to determine immunoreactive LH. Their results suggest that previous studies which used RIA to measure immunoreactivity LH may need to be re-evaluated, at least at low concentrations.
The results of this study confirm a positive bias of LH results by RIA when compared to the IRMA. However, it is not clear which method, if either, gives the most accurate result. The limitations of any method used for measuring immunoreactive hormone should be taken into account when interpreting B/I ratios.
